Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.73M Buy
43,438
+21,108
+95% +$1.47M 0.05% 617
2025
Q4
$1.48M Sell
22,330
-32,803
-59% -$2.12M 0.04% 751
2025
Q3
$3.71M Buy
55,133
+44,555
+421% +$3.53M 0.19% 68
2025
Q2
$923K Sell
10,578
-10,574
-50% -$829K 0.04% 714
2025
Q1
$1.44M Buy
21,152
+11,136
+111% +$909K 0.07% 374
2024
Q4
$779K Sell
10,016
-19,088
-66% -$1.41M 0.06% 444
2024
Q3
$1.95M Buy
+29,104
New +$2.39M 0.14% 154
2024
Q2
Sell
-4,453
Closed -$618K 2006
2024
Q1
$618K Buy
+4,453
New +$560K 0.08% 361
2023
Q4
Sell
-6,447
Closed -$602K 1712
2023
Q3
$602K Buy
6,447
+1,864
+41% +$210K 0.1% 293
2023
Q2
$589K Sell
4,583
-1,544
-25% -$187K 0.11% 277
2023
Q1
$712K Sell
6,127
-2,788
-31% -$312K 0.15% 129
2022
Q4
$1.01M Sell
8,915
-3,397
-28% -$373K 0.21% 84
2022
Q3
$992K Buy
12,312
+4,948
+67% +$419K 0.25% 51
2022
Q2
$549K Sell
7,364
-1,248
-14% -$114K 0.22% 99
2022
Q1
$1.1M Buy
8,612
+6,896
+402% +$754K 0.48% 27
2021
Q4
$230K Buy
+1,716
New +$247K 0.13% 308
2021
Q2
Sell
-7,960
Closed -$715K 868
2021
Q1
$715K Buy
+7,960
New +$747K 0.35% 32

Other funds holding DXCM

XTX Topco's DXCM Position: Q1 2026 in Review

XTX Topco increased its DexCom (DXCM) stake by 95% in Q1 2026, buying an estimated $1.47M and bringing the position to 43,438 shares worth $2.73M. The position accounts for 0.05% of the portfolio, ranked #617.

XTX Topco first reported a position in DXCM in Q1 2021 and has held it in 17 quarters since. The position peaked at $3.71M in Q3 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • XTX Topco held 43,438 shares of DexCom worth $2.73M as of Q1 2026.
  • XTX Topco bought 21,108 DexCom shares in Q1 2026, an estimated $1.47M.
  • DexCom made up 0.05% of XTX Topco's portfolio in Q1 2026, its #617 holding.
  • XTX Topco first reported a position in DexCom in Q1 2021 and has held it in 17 quarters since.
  • XTX Topco's DexCom position peaked at $3.71M in Q3 2025.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.